Trademark: BERGENBIO 2240737
Word
BERGENBIO
Device Descrption:
PATTERN OF 6 DOTS WITH HEXAGON
ID
2240737
Trademark Type
Figurative
Status
Protected: Registered/protected
Application Date
22 October 2021
Registration Date
22 October 2021
Renewal Date
22 October 2031
Owner(s)
Service
Adams Pluck
Goods and Services:
Class 1:
Chemicals, chemical compounds, biochemicals and biologic compounds for scientific or industrial purposes, or for use in laboratories or in research; chemicals, chemical compounds, biochemicals and biologic compounds for analytical and diagnostic purposes in laboratory use; chemicals, chemical compounds, biochemicals and biologic compounds for the experimental production of drugs, pharmaceutical products and biotechnological preparations; chemicals, chemical compounds, biochemicals and biologic compounds for use in the development and manufacture of diagnostic products and services, drugs and pharmaceutical products, including for the diagnosis and treatment of cancers, including lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; chemicals, chemical compounds, biochemicals and biologic compounds for use in the development and manufacture of drugs and pharmaceutical products, including drugs and pharmaceutical products that target axl, akt3 or other genes, proteins, kinases and enzymes; active chemical and biochemical ingredients and components for use in the development and manufacture of diagnostic products and services, drugs and pharmaceutical products, including for the diagnosis and treatment of cancers, including lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; antibodies, small molecules and proteins for scientific or industrial purposes, or for use in laboratories or in research; antibodies, small molecules and proteins for use in the development and manufacture of diagnostic products and services, drugs and pharmaceutical products, including for the diagnosis and treatment of cancers, including lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; antibodies, small molecules and proteins for use in the development and manufacture of drugs and pharmaceutical products, including drugs and pharmaceutical products that target axl, akt3 or other genes, proteins, kinases and enzymes; antibodies, anti-axl antibodies, small molecules, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins for scientific or industrial purposes, or for use in laboratories or in research; antibodies, anti-axl antibodies, small molecules, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins for use in the development and manufacture of diagnostic products and services, drugs and pharmaceutical products, including for the diagnosis and treatment of cancers, including lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; antibodies, anti-axl antibodies, small molecules, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins for use in the development and manufacture of drugs and pharmaceutical products, including drugs and pharmaceutical products that target axl, akt3 or other genes, proteins, kinases and enzymes; proteins for use in kinase inhibiting technology [other than for medical use].
Chemicals, chemical compounds, biochemicals and biologic compounds for scientific or industrial purposes, or for use in laboratories or in research; chemicals, chemical compounds, biochemicals and biologic compounds for analytical and diagnostic purposes in laboratory use; chemicals, chemical compounds, biochemicals and biologic compounds for the experimental production of drugs, pharmaceutical products and biotechnological preparations; chemicals, chemical compounds, biochemicals and biologic compounds for use in the development and manufacture of diagnostic products and services, drugs and pharmaceutical products, including for the diagnosis and treatment of cancers, including lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; chemicals, chemical compounds, biochemicals and biologic compounds for use in the development and manufacture of drugs and pharmaceutical products, including drugs and pharmaceutical products that target axl, akt3 or other genes, proteins, kinases and enzymes; active chemical and biochemical ingredients and components for use in the development and manufacture of diagnostic products and services, drugs and pharmaceutical products, including for the diagnosis and treatment of cancers, including lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; antibodies, small molecules and proteins for scientific or industrial purposes, or for use in laboratories or in research; antibodies, small molecules and proteins for use in the development and manufacture of diagnostic products and services, drugs and pharmaceutical products, including for the diagnosis and treatment of cancers, including lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; antibodies, small molecules and proteins for use in the development and manufacture of drugs and pharmaceutical products, including drugs and pharmaceutical products that target axl, akt3 or other genes, proteins, kinases and enzymes; antibodies, anti-axl antibodies, small molecules, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins for scientific or industrial purposes, or for use in laboratories or in research; antibodies, anti-axl antibodies, small molecules, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins for use in the development and manufacture of diagnostic products and services, drugs and pharmaceutical products, including for the diagnosis and treatment of cancers, including lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; antibodies, anti-axl antibodies, small molecules, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins for use in the development and manufacture of drugs and pharmaceutical products, including drugs and pharmaceutical products that target axl, akt3 or other genes, proteins, kinases and enzymes; proteins for use in kinase inhibiting technology [other than for medical use].
Class 5:
Drugs for medical purposes, drugs and pharmaceutical products; drugs for medical purposes, drugs and pharmaceutical products incorporating antibodies, anti-axl antibodies, small molecules, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors, or selective inhibitors of cell surface proteins; drugs for medical purposes, drugs and pharmaceutical products, including for treatment of cancers, including lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; drugs and pharmaceutical products including drugs and pharmaceutical products that target axl, akt3 or other genes, proteins, kinases and enzymes; drugs and pharmaceutical products for use in oncology; chemicals, chemical compounds, biochemicals and biologic compounds for medical purposes; diagnostic test kits for medical laboratory analysis; diagnostic kits for use in disease testing; antibodies, small molecules and proteins for medical purposes; antibodies, anti-axl antibodies, small molecules, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins for medical purposes; protein synthesis inhibitors.
Drugs for medical purposes, drugs and pharmaceutical products; drugs for medical purposes, drugs and pharmaceutical products incorporating antibodies, anti-axl antibodies, small molecules, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors, or selective inhibitors of cell surface proteins; drugs for medical purposes, drugs and pharmaceutical products, including for treatment of cancers, including lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; drugs and pharmaceutical products including drugs and pharmaceutical products that target axl, akt3 or other genes, proteins, kinases and enzymes; drugs and pharmaceutical products for use in oncology; chemicals, chemical compounds, biochemicals and biologic compounds for medical purposes; diagnostic test kits for medical laboratory analysis; diagnostic kits for use in disease testing; antibodies, small molecules and proteins for medical purposes; antibodies, anti-axl antibodies, small molecules, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins for medical purposes; protein synthesis inhibitors.
Class 42:
Drug discovery and drug development services; scientific research services; research and development services in the fields of oncology and immunology; scientific research services related to the role of axl and related kinase signalling in disease; scientific research services related to axl biology and its role in mediating aggressive disease; scientific research services related to biomarker discovery; scientific services related to the development of diagnostic products and services, including relating to the treatment of cancers, including lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; scientific research services related to improving the efficacy of chemotherapy, targeted cancer therapy and immuno-oncology drugs; research and development services in the field of antibodies, small molecules and proteins; conducting or providing research and development services for others in the field of antibody and small molecule technology; medical and biotechnology research services; research, development and engineering of antibodies, small molecules and proteins, including anti-axl antibodies, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins; laboratory services relating to the production of antibodies, small molecules and proteins, including anti-axl antibodies, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins; researching and developing the use of antibodies, small molecules and proteins for the treatment of patients; information, consultancy and advisory services related to the aforesaid.
Drug discovery and drug development services; scientific research services; research and development services in the fields of oncology and immunology; scientific research services related to the role of axl and related kinase signalling in disease; scientific research services related to axl biology and its role in mediating aggressive disease; scientific research services related to biomarker discovery; scientific services related to the development of diagnostic products and services, including relating to the treatment of cancers, including lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; scientific research services related to improving the efficacy of chemotherapy, targeted cancer therapy and immuno-oncology drugs; research and development services in the field of antibodies, small molecules and proteins; conducting or providing research and development services for others in the field of antibody and small molecule technology; medical and biotechnology research services; research, development and engineering of antibodies, small molecules and proteins, including anti-axl antibodies, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins; laboratory services relating to the production of antibodies, small molecules and proteins, including anti-axl antibodies, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins; researching and developing the use of antibodies, small molecules and proteins for the treatment of patients; information, consultancy and advisory services related to the aforesaid.